1.Metal stent implantation in treatment of portal vein cavernous transformation
Lei LI ; Xinwei HAN ; Tengfei LI ; Wenguang ZHANG ; Pengli ZHOU ; Suya WANG ; Yi FANG
Journal of Practical Radiology 2016;(2):270-273
Objective To explore the efficacy and safety of percutaneous transhepatic portal vein or transjugular intrahepatic portosystemie shunt (TIPS)to implant the portal vein metallic stent in treatment of cavernous transformation of portal vein (CTPV).Methods Clinical and imaging data of 8 patients with CTPV were retrospectively analyzed who were treated in our hospital.All patients were treated with metallic stent implantation in portal vein including 3 patients by TIPS and 5 by percutaneous transhepatic portal vein.Results All patients were successful in the stent implantation without any occurrence of serious complications such as intra-abdominal hemorrhage and so on.Intraoperative angiography showed blood circulated freely in these stents.1 day-2 weeks later,the patients symptoms of abdominal pain and gastrointestinal bleeding were obviously relieved or disappeared.Follow up 1 month-3 years,1 patient with stent occlusion after one year of operation,the blood flow recovery after stent reimplantation,and the remaining patients,color doppler ultrasound reflected patency of blood flows in their stents.No one suffered from gastrointestinal bleeding or abdominal pain again.Conclusion Implantation of portal vein metallic stent via percutaneous transhepatic portal vein or via TIPS in treatment of cavernous transformation of portal vein is safe and effective.
2.Application of CT Radiomics in Predicting Differentiation Level of Lung Adenocarcinoma
Shuai ZHANG ; Peng HAN ; Suya ZHANG ; Dingli YE ; Zhicheng HUANG
Chinese Journal of Medical Instrumentation 2024;48(6):591-594
Objective To investigate the value of prediction of the differentiation level in lung adenocarcinoma based on CT radiomics model.Methods Data from 507 patients with postoperative pathological confirmed lung adenocarcinoma and clearly defined differentiation level of lung adenocarcinoma were retrospective analyzed.The enrolled cases were divided into poorly differentiation group and moderate-to-high differentiation group based on the grading criteria.CT image features were extracted,and seven machine learning algorithms were used to construct prediction models to obtain the AUC,accuracy,specificity,and sensitivity.Results The poorly differentiation group consisted of 175 cases,while the moderate-to-high differentiation group had 332 cases.The XGBoost model demonstrated the best performance,with the AUC,accuracy,specificity,and sensitivity of this model on the validation set being 0.878,0.829,0.667,and 0.727,respectively.Conclusion CT radiomics model can effectively predict the differentiation level of poorly differentiation and moderate-to-high differentiation in lung adenocarcinoma.
3.Clinical study on patient-derived organoids as a predictive model for assessing treatment response in pancreatic cancer
Suya SHEN ; Jingjing LI ; Hao CHENG ; Wenyan GUAN ; Zhiwen LI ; Xiao FU ; Yingzhe HU ; Zhenghua CAI ; Yuqing HAN ; Yudong QIU
Chinese Journal of General Surgery 2023;38(9):655-661
Objective:To construct a biospecimen bank of patient derived organoids (PDOs) from pancreatic cancer tissues and to explore the feasibility of PDOs drug sensitivity assay technology to guide chemotherapy drug selection for pancreatic cancer.Methods:Pancreatic cancer tissue specimens obtained after surgical resection and puncture biopsy from Mar 2020 to Dec 2022 at Drum Tower Hospital, Nanjing University School of Medicine were collected. Pancreatic cancer PDOs were cultured in vitro and histologically identified; PDOs were treated with gemcitabine, Nab-paclitaxel, fluorouracil, Oxaliplatin, and Irinotecan and cell viability was measured to analyze the correlation between PDOs drug sensitivity and the actual clinical treatment response.Results:The PDOs can reproduce the pathological features of corresponding tumor tissues; the sensitivity of different PDOs to the same chemotherapeutic drug is significantly different; The sensitivity of PDOs was highly consistent with the actual treatment effect of the corresponding patients 75.76% (25/33); organoid organ-based susceptibility testing had predictive value for the treatment response of patients (AUC=0.733, 95% CI: 0.546-0.919, P<0.05). Conclusion:A biobank of pancreatic cancer PDOs was successfully constructed, and the drug susceptibility test results were significantly correlated with the actual medication response of patients, suggesting that the drug susceptibility test technology based on PDOs has the potential to guide individualized chemotherapy for pancreatic cancer.
4.Qualitative research on life experience of aged residents living in private rest homes in Shijiazhuang
Shuqing HAN ; Guoxin LI ; Suya YUAN ; Zhao ZHANG ; Xiaoci HE ; Suzhai TIAN
Chinese Journal of Modern Nursing 2017;23(1):52-56
Objective To investigate the life experience of aged residents living in private rest homes in Shijiazhuang,so as to provide reference for improving their quality of life (QOL).Methods Semi-structured interview was used to investigate 12 residents living in three private rest homes,and the data was analyzed by phenomenological analysis.Results The life experience of aged residents living in private rest homes was summarized with four related topics:high-quality experience,life adaptation,conflict and expectation. Conclusions The life experience of aged residents living in private rest homes in Shijiazhuang is mixed with joy and concern,and it is closely related with the physical condition,operation management mode and service level of retirement organizations. The QOL of aged residents living in private rest homes needs the joint efforts of government,organizations,aged residents′ relatives and friends. They should positively resolve the conflict, promote adaption and improve happiness,so as to improve the life experience of aged residents living in private rest homes.
5.Study on the relationship between HBV gene mutation and disease progression in patients with hepatitis B virus infection
Suya HAN ; Shuang ZHANG ; Lin TANG ; Qudong SU ; Fuzhen WANG ; Feng WANG ; Hui ZHENG ; Feng QIU ; Hongyi LI ; Yu WANG ; Liping SHEN
Chinese Journal of Experimental and Clinical Virology 2024;38(1):21-28
Objective:To analyze the whole genome sequence and key site mutations of hepatitis B virus (HBV) in patients with different stages of disease progression, and to understand the relationship between HBV genetic characteristics and disease progression.Methods:Serum samples and basic information of hepatitis B patients with asymptomatic HBV carrier, chronic hepatitis B patients, cirrhosis patients and primary hepatocellular carcinoma patients were collected. Nested PCR was used to amplify the samples to obtain HBV whole gene sequences. Phylogenetic trees were constructed to determine the genotype of the samples, and gene mutations of the samples were analyzed combined with reference sequences of each type.Results:A total of 256 samples were successfully amplified, including 68 asymptomatic HBV carrier patients, 118 CHB patients, 15 LC patients and 55 HCC patients, and five genotypes (B, C, D, I and C/D) were detected. The result of comparative analysis showed that the mutation rate of 56 nucleotide sites was significantly different among the four groups ( P<0.05). In addition to the discovery of C105T, A1762T/G1764A and G1899A and other previously reported key site mutations, the mutation rates of T53A, C1485T and C1628T in newly diagnosed HCC group were significantly higher than those in other groups, and the mutation rates of T2150G and T2151C in asymptomatic HBV infection group were significantly higher than those in other groups. A total of 26 sequences were deleted, mainly distributed in the pre-C and pre-S regions. The deletion mutation rate in the HCC group was significantly higher than that in the other groups. Conclusions:The data of this study indicate that some nucleotide substitution mutations and deletion mutations may be closely related to the occurrence and development of HBV-related diseases, and HCC patients are more likely to have gene mutations than non-HCC patients. These result provide a reference for understanding the relationship between viral mutation and the progression of HBV infection-related diseases.